Supramolecular copolymer modified statin-loaded discoidal rHDLs for atherosclerotic anti-inflammatory therapy by cholesterol efflux and M2 macrophage polarization

被引:12
作者
Zhang, Qiqi [1 ]
He, Jianhua [1 ]
Xu, Fengfei [1 ]
Huang, Xinya [1 ]
Wang, Yanyan [1 ]
Zhang, Wenli [1 ]
Liu, Jianping [1 ]
机构
[1] China Pharmaceut Univ, Dept Pharmaceut, Nanjing 210009, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
HIGH-DENSITY-LIPOPROTEIN; LOADING ATORVASTATIN; BETA-CYCLODEXTRIN; IN-VITRO; NANOPARTICLES; INFLAMMATION; PHARMACOKINETICS; METABOLISM; MODULATION; RELEASE;
D O I
10.1039/d1bm00610j
中图分类号
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号
0805 ; 080501 ; 080502 ;
摘要
Foam cells with the pro-inflammatory macrophage phenotype (M1) play an essential role in atherosclerosis progression. Either cellular cholesterol removal or drug intervention was reported to polarize M1 into the anti-inflammatory phenotype (M2) for atherosclerosis regression. These might be realized simultaneously by drug-loaded discoidal reconstituted high-density lipoproteins (d-rHDLs) with the functions of cellular cholesterol efflux and targeted drug delivery on macrophages. However, cholesterol reception can drive the remodelling of d-rHDLs, which serves to release drugs specifically in the atherosclerotic plaque but might incur premature drug leakage in blood circulation. Given that, the proposed strategy is to inhibit the remodelling behaviour of the carrier in blood circulation and responsively accelerate it under the atherosclerotic microenvironmental stimulus. Herein, atorvastatin calcium-loaded d-rHDL was modified by a PEGylated ferrocene/beta-cyclodextrin supramolecular copolymer (PF/TC) to construct ROS-responsive PF/TC-AT-d-rHDL, which is expected to possess plasma stability and biosafety as well as triggered drug release by cholesterol efflux promotion. As a result, PF/TC-AT-d-rHDL could responsively dissemble into beta-cyclodextrin modified AT-d-rHDL under the ROS-triggered dissociation of PF/TC, therefore exhibiting increased cholesterol efflux from the cholesterol donor and drug release through the remodelling behaviour of the carrier in vitro. Moreover, PF/TC-AT-d-rHDL enhanced cellular cholesterol removal in foam cells after response to ROS, inhibiting intracellular lipid deposition compared with other d-rHDL carriers. Interestingly, cellular drug uptake was significantly promoted upon cellular cholesterol removal by restoring the permeability and fluidity of foam cell membranes as indicated by flow cytometry and fluorescence polarization analysis, respectively. Importantly, compared with untreated foam cells, PF/TC-AT-d-rHDL obviously increased the ratio of M2/M1 by 6.3-fold, which was even higher than the effect of PF/TC-d-rHDL (3.4-fold) and free drugs (1.9-fold), revealing that PF/TC-AT-d-rHDL synergistically promoted the M2 polarization of macrophages. Accordingly, PF/TC-AT-d-rHDL boosted the secretion of anti-inflammatory cytokines and inhibited that of inflammatory cytokines. Collectively, PF/TC-AT-d-rHDL exerted synergistic M2 polarization effects on foam cells for atherosclerotic immunomodulatory therapy via responsively mediating cholesterol efflux and delivering drugs.
引用
收藏
页码:6153 / 6168
页数:16
相关论文
共 71 条
  • [31] The transcription factor MafB promotes anti-inflammatory M2 polarization and cholesterol efflux in macrophages
    Kim, Hwijin
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [32] Functionally defective high-density lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis
    Kontush, Anatol
    Chapman, M. John
    [J]. PHARMACOLOGICAL REVIEWS, 2006, 58 (03) : 342 - 374
  • [33] The studies of PLGA nanoparticles loading atorvastatin calcium for oral administration in vitro and in vivo
    Li, Zhenbao
    Tao, Wenhui
    Zhang, Dong
    Wu, Chunnuan
    Song, Binbin
    Wang, Shang
    Wang, Tianyang
    Hu, Mingming
    Liu, Xiaohong
    Wang, Yongjun
    Sun, Yinghua
    Sun, Jin
    [J]. ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 12 (03) : 285 - 291
  • [34] Hyaluronic acid-decorated reconstituted high density lipoprotein targeting atherosclerotic lesions
    Liu, Lisha
    He, Hongliang
    Zhang, Mengyuan
    Zhang, Shuangshuang
    Zhang, Wenli
    Liu, Jianping
    [J]. BIOMATERIALS, 2014, 35 (27) : 8002 - 8014
  • [35] Biofunctional Polymer Lipid Hybrid High-Density Lipoprotein Mimicking Nanoparticles Loading Anti-miR155 for Combined Antiatherogenic Effects on Macrophages
    Lu, Jing
    Zhao, Yi
    Zhou, Xiaoju
    He, Jian Hua
    Yang, Yun
    Jiang, Cuiping
    Qi, Zitong
    Zhang, Wenli
    Liu, Jianping
    [J]. BIOMACROMOLECULES, 2017, 18 (08) : 2286 - 2295
  • [36] Tailoring of Biomimetic High-Density Lipoprotein Nanostructures Changes Cholesterol Binding and Efflux
    Luthi, Andrea J.
    Zhang, Heng
    Kim, Dongwoo
    Giljohann, David A.
    Mirkin, Chad A.
    Thaxton, C. Shad
    [J]. ACS NANO, 2012, 6 (01) : 276 - 285
  • [37] Regulation of M1-type and M2-type macrophage polarization in RAW264.7 cells by Galectin-9
    Lv, Ran
    Bao, Qi
    Li, Yan
    [J]. MOLECULAR MEDICINE REPORTS, 2017, 16 (06) : 9111 - 9119
  • [38] Reconstituted high-density lipoproteins: novel biomimetic nanocarriers for drug delivery
    Ma, Xinyi
    Song, Qingxiang
    Gao, Xiaoling
    [J]. ACTA PHARMACEUTICA SINICA B, 2018, 8 (01) : 51 - 63
  • [39] MAHLEY RW, 1984, J LIPID RES, V25, P1277
  • [40] Uptake and metabolism of novel biodegradable poly(glycerol-adipate) nanoparticles in DAOY monolayer
    Meng, W.
    Parker, T. L.
    Kallinteri, P.
    Walker, D. A.
    Higgins, S.
    Hutcheon, G. A.
    Garnett, M. C.
    [J]. JOURNAL OF CONTROLLED RELEASE, 2006, 116 (03) : 314 - 321